ATTENTION Fortrea Holdings Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / October 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fortrea Holdings Inc. ("Fortrea Holdings Inc.") (NASDAQ:FTRE) concerning possible violations of federal securities laws. Jefferies downgraded Fortrea on September 25, 2024, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE
NEW YORK, NY / ACCESSWIRE / October 13, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Fortrea Holdings Inc. ("Fortrea" or the "Company") (NASDAQ:FTRE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
An Investigation Has Commenced on Behalf of Fortrea Holdings Inc. Shareholders. Contact Levi & Korsinsky to Discuss your FTRE Losses
NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fortrea Holdings Inc. ("Fortrea Holdings Inc.") (NASDAQ:FTRE) concerning possible violations of federal securities laws. Jefferies downgraded Fortrea on September 25, 2024, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE
NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Fortrea Holdings Inc. ("Fortrea" or the "Company") (NASDAQ:FTRE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Fortrea Holdings Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - FTRE
NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fortrea Holdings Inc. ("Fortrea Holdings Inc.") (NASDAQ:FTRE) concerning possible violations of federal securities laws. Jefferies downgraded Fortrea on September 25, 2024, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.
Bronstein, Gewirtz & Grossman, LLC Encourages Fortrea Holdings Inc. (FTRE) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / October 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fortrea Holdings Inc. ("Fortrea" or "the Company") (NASDAQ:FTRE). Investors who purchased Fortrea securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FTRE.
Levi & Korsinsky Reminds Fortrea Holdings Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - FTRE
NEW YORK, NY / ACCESSWIRE / October 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fortrea Holdings Inc. ("Fortrea Holdings Inc.") (NASDAQ:FTRE) concerning possible violations of federal securities laws. Jefferies downgraded Fortrea on September 25, 2024, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Fortrea Holdings Inc. (FTRE) And Encourages Shareholders to Connect
NEW YORK CITY, NY / ACCESSWIRE / October 10, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fortrea Holdings Inc. ("Fortrea" or "the Company") (NASDAQ:FTRE). Investors who purchased Fortrea securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FTRE.
Investors who lost money on Fortrea Holdings Inc. should contact Levi & Korsinsky about an ongoing investigation - FTRE
NEW YORK, NY / ACCESSWIRE / October 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fortrea Holdings Inc. ("Fortrea Holdings Inc.") (NASDAQ:FTRE) concerning possible violations of federal securities laws. Jefferies downgraded Fortrea on September 25, 2024, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.
ATTENTION FTRE SHAREHOLDERS: Investors who lost money on Fortrea Holdings Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
NEW YORK, NY / ACCESSWIRE / October 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fortrea Holdings Inc. ("Fortrea Holdings Inc.") (NASDAQ:FTRE) concerning possible violations of federal securities laws. Jefferies downgraded Fortrea on September 25, 2024, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.
Bronstein, Gewirtz & Grossman, LLC Encourages Fortrea Holdings Inc. (FTRE) Stockholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / October 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fortrea Holdings Inc. ("Fortrea" or "the Company") (NASDAQ:FTRE). Investors who purchased Fortrea securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FTRE.
Investors who lost money on Fortrea Holdings Inc. should contact Levi & Korsinsky about an ongoing investigation - FTRE
NEW YORK, NY / ACCESSWIRE / October 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fortrea Holdings Inc. ("Fortrea Holdings Inc.") (NASDAQ:FTRE) concerning possible violations of federal securities laws. Jefferies downgraded Fortrea on September 25, 2024, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.
